Industry’s Efforts Impact More Than 1.6 Million Students in Past Five Years

WASHINGTON, D.C. (January 22, 2014) – Innovative biopharmaceutical companies and their corporate foundations are making significant contributions to U.S. science, technology, engineering and math (STEM) education through a broad range of local, state and national level programs and initiatives aimed at elementary through post-secondary education, according to a first-of-its-kind report by the Battelle Technology Partnership Practice.

Addressing Gaps in U.S. STEM Education

01.22.14 | By

It’s been widely reported that the United States has a science, technology, engineering and math (STEM) education problem. As we fall behind other countries in STEM proficiencies, our leadership in innovation across sectors is at risk. In the biopharmaceutical research industry, we are dependent on highly skilled workers with extensive STEM knowledge to develop novel, life-saving medicines and diagnostics.

backgrounder - stem

stem factsheet

Nerds Rule the Universe

01.21.14 | By

The next new addition to our “I am Research, Progress, Hope” series is a scientist from Pfizer who works in neuroscience – leading a multi-disciplinary team focusing on Alzheimer’s and other serious diseases of the brain including schizophrenia.

STEM Saves Lives Forum

01.15.14 | By

Just one week from today, PhRMA is joining with U.S. News and World Report for a forum on a very important topic: Science, math, engineering and technology education, better known as STEM education. Numerous studies have shown that the United States has a STEM problem. We are falling behind other countries, with our students ranking in the bottom half of OECD nations in both science and math literacy.

Trials of New Medicines

01.10.14 | By

Those who advocate more aggressive outreach to patients to talk about the potential benefits and importance of clinical research would certainly have felt vindicated during the roll out of "Research in Your Backyard: Pharmaceutical Clinical Trials in Iowa" yesterday in Des Moines.

2014 – A Year of Opportunity

01.10.14 | By

While 2013 was a great year, 2014 promises to be even better. As we look ahead, our focus on facilitating thoughtful discussions on some of the most important health care topics will continue.

Nearly 1,300 Clinical Trials Conducted in the State Since 1999

DES MOINES, IA (January 9, 2014) – Working with Iowa research institutions, including the members of the new Iowa Coalition of Clinical Researchers (ICCR), the nation’s biopharmaceutical research companies have conducted 1,287 clinical trials of new medicines in the state since 1999, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). The total reflects an increase of almost 200 trials in just the last seven months.

Research in Iowa

Pages

Subscribe to RSS - Innovation